biotechbeta (@biotechbeta) profile picture

Nowadays people know the price of everything, and the value of nothing.

Joined September 2021
Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)Photo by biotechbeta (@biotechbeta)
biotechbeta retweeted
you pity the moth confusing a lamp for the moon, yet here you are confusing a screen for the world
790
35,282
1,842
185,904
11,755,601
Beginning to thing the next wave of IO target aren't all that goose 馃様
3
3
65
7,482
biotechbeta retweeted
Oncology M&A deals from Barclays. For many it's too early to tell, but hard to find deals that paid off significantly. Of 35 deals, there were only two deals that look good retrospectively: NVS/ECYT and SGEN/CASC. None of the top 10 deals can be viewed as lucrative imo...
8
14
2
81
22,512
If you ain't first you last...
Keytruda now doing over $5B per quarter. All hail the King.
1
1
1
13
The PROTAC gold rush. Investment in small-molecule protein degraders is surging, but their drawbacks, limitations and risks are becoming clear go.nature.com/3sbaWjb
1
32
5
149
Barclays' Boston Biotech Bus Trip - Comp sheet for SMID cap oncology companies
3
17